Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition

Novo Nordisk is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase comes despite supply constraints and competition from Eli Lilly.
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly, reported Bloomberg on Friday.